Evidence map›Paper›PMID 41178922›Full record

ArticleWorld journal of clinical oncology2025

Ropeginterferon alfa-2b

Leo Tom, Shinjit Mani, Akash Rawat, Mina Nan, Shruti Manoj Mundada, Basel Al Khatib, Aparna Gopinath, Osama Taj, Namitha Salahuddin, Farzana Shaju and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Leo TomDepartment of Clinical Oncology, K S Hegde Medical Academy, Mangalore 575018, Karnātaka, India.
Shinjit ManiDepartment of Medical Oncology, Chittaranjan National Cancer Institute, Kolkata 700160, West Bengal, India.
Akash RawatDepartment of General Medicine, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehra Dun 248016, Uttarākhand, India.
Mina NanDepartment of Internal Medicine, Capital Health Regional Medical Center, NJ 07002, Trenton, United States.
Shruti Manoj MundadaDepartment of Clinical Oncology, Gandhi Medical College and Hospital, Hyderabad 500003, Telangāna, India.
Basel Al KhatibDepartment of Clinical Oncology, Alfaisal University, Riyadh 11533, Saudi Arabia.
Aparna GopinathDepartment of Clinical Oncology, Government Medical College Trivandrum, Thiruvananthapuram 695011, Kerala, India.
Osama TajDepartment of Clinical Oncology, Creek General Hospital, Karachi 75190, Sindh, Pakistan.
Namitha SalahuddinDepartment of Clinical Oncology, Gulf Medical University, Ajman 4184, United Arab Emirates.
Farzana ShajuDepartment of Clinical Oncology, Sree Narayana Institute of Medical Sciences, Ernakulam 683594, Kerala, India.
Syeda ParsaDepartment of Clinical Oncology, Chandka Medical College, Sindh 77280, Pakistan.
Mahmud AbdurrahmanDepartment of Clinical Oncology, Richmond Gabriel University, Kingstown VC0100, Saint George, Saint Vincent and the Grenadines.
Ashesh DasDepartment of Clinical Oncology, KPC Medical College and Hospital, Kolkata 700001, West Bengal, India.
Mirza Muhammad Hadeed KhawarDepartment of Clinical Oncology, Services Institute of Medical Sciences, Lahore 40050, Punjab, Pakistan.
Ali SherDepartment of Clinical Oncology, International University of Kyrgyzstan, ISM IUK Eastern Campus, Bishkek 720054, Chüy, Kyrgyzstan. aligondal78679@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolycythemia vera (PV) is a myeloproliferative neoplasm characterized by excessive blood cell production, which increases the risk of thrombosis. Ropeginterferon alfa-2b (RI) offers potential advantages over standard therapy (ST; including phlebotomy, hydroxyurea, and aspirin) by achieving hematologic and molecular responses. However, its comparative efficacy and safety remain understudied. We hypothesized that RI would improve hematologic and molecular outcomes but may differ in safety profiles compared to ST.

aimTo evaluate the efficacy and safety of RI

methodsThis Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant meta-analysis included randomized controlled trials comparing RI to ST in adult PV patients. PubMed, EMBASE, ClinicalTrials.gov, and ScienceDirect were searched from inception to July 2025. Outcomes included complete hematological response (CHR), molecular response, AEs leading to discontinuation, JAK2V617F allele burden, thrombotic events, and phlebotomy frequency. Pooled odds ratios (ORs) and MD with 95% confidence intervals (95%CIs) were calculated using random-effects models. Risk of bias was assessed with Cochrane RoB 2; evidence certainty was evaluated

resultsFive studies involving 477 RI and 456 ST patients were included. RI significantly improved CHR (OR = 2.14, 95%CI: 1.18-3.88,

conclusionRI offers superior hematologic and molecular responses compared to ST in PV but is associated with higher discontinuation rates due to AEs. Comparable thrombotic risk and reduced phlebotomy needs highlight its potential, though tolerability requires careful management. The high heterogeneity in certain outcomes and potential for publication bias warrant cautious interpretation of these findings. Further long-term studies are needed to optimize dosing and patient selection.

Indexed as

Adverse eventsHematologic responseHydroxyureaMolecular responsePolycythemia veraRopeginterferon alfa-2b

Identifiers

PMID41178922
PMCPMC12576534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.